Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8208813 | 0.88 | F10 (0.68) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL3558738 | 0.82 | F10 (1.00) | F10 | |
| SCHEMBL8203512 | 0.80 | F10 (0.80) | F10 | |
| SCHEMBL8266510 | 0.78 | F10 (0.68) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL1096902 | 0.78 | F10 (0.63) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL2191043 | 0.77 | F10 (0.63) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL2191033 | 0.77 | F10 (0.63) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL4909468 | 0.77 | F10 (0.62) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL3451331 | 0.76 | F10 (0.63) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL4911432 | 0.76 | F10 (0.59) | F10ABCB11F2ST14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| WO-2008049747-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | F12, F11, F2 | F10 4/4885ABCB11 3035/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.